135 related articles for article (PubMed ID: 11994888)
1. A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
Weiser M; Rotmensch HH; Korczyn AD; Hartman R; Cicin-Sain A; Anand R;
Int J Geriatr Psychiatry; 2002 Apr; 17(4):343-6. PubMed ID: 11994888
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of risperidone.
Davidson M
J Clin Psychiatry; 2001; 62 Suppl 21():26-8. PubMed ID: 11584985
[TBL] [Abstract][Full Text] [Related]
4. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
5. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
6. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
8. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
[No Abstract] [Full Text] [Related]
9. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.
Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Greenspan A
Int J Geriatr Psychiatry; 2005 Dec; 20(12):1153-7. PubMed ID: 16315159
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Burns A; Spiegel R; Quarg P
Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
[TBL] [Abstract][Full Text] [Related]
11. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
[TBL] [Abstract][Full Text] [Related]
13. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
14. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Farlow MR
Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
[TBL] [Abstract][Full Text] [Related]
15. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Tune LE
J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
17. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of behavioral disorders in dementia with risperidone in psychogeriatric out-patients].
Kurz A; Delius-Stute H; Rettig K; Schwalen S
MMW Fortschr Med; 2003 Oct; 145 Suppl 3():89-95. PubMed ID: 15490773
[TBL] [Abstract][Full Text] [Related]
19. [Biological therapies of behavioral and psychological symptoms of dementia: update and prospects].
Gallarda T; Olie JP
Encephale; 2000; 26(3):72-80. PubMed ID: 10951909
[TBL] [Abstract][Full Text] [Related]
20. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Scheepmaker AJ; Horstink MW; Hoefnagels WH; Strijks FE
Ned Tijdschr Geneeskd; 2003 Jan; 147(1):32-5. PubMed ID: 12564296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
